Prediction of sotorasib response duration and identification of clinically actionable resistance mechanisms using an RNA-based patient classifier
KRAS mutations are among the most prevalent oncogenic drivers [...]
KRAS mutations are among the most prevalent oncogenic drivers [...]
KRAS mutations drive approximately 25% of human cancers, resulting [...]
The WEE1 kinase is a central regulator of G2/M [...]
Molecular biomarkers in non-small cell lung cancer (NSCLC), primarily [...]
KRAS inhibitors (KRASi) have the potential to transform treatment [...]
Genialis krasID analyzes foundational aspects of KRAS biology using RNA-sequencing [...]
Abstract:This study investigates the prevalence of genomic alterations in [...]
This study explores the distribution of genomic alterations in [...]
This study introduces a machine learning model that uses [...]
Traditional biomarkers often fail to capture the dynamic nature [...]